Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois. Show more

1000 Skokie Boulevard, Wilmette, IL, 60091, United States

Biotechnology
Healthcare
Start AI Chat

Market Cap

372.9M

52 Wk Range

$26.05 - $105.00

Previous Close

$55.80

Open

$56.29

Volume

352,702

Day Range

$55.88 - $61.30

Enterprise Value

546.6M

Cash

143.7M

Avg Qtr Burn

-2.091M

Insider Ownership

23.72%

Institutional Own.

82.83%

Qtr Updated

09/30/25